Back
Blueprint Medicines Stock Price Chart
Former Zillow execs target $1.3T market
This is a paid advertisement for Pacaso's Regulation A offering. Please read the offering circular and related risks at invest.pacaso.com.
Sell
49
BPMC
Blueprint Medicines
Last Price:
$97.57
Seasonality Move:
13.41%
7 Day Trial
ALL ACCESS PASS
$
7
Top investors are buying this "unlisted" stock
This is a paid advertisement for Pacaso's Regulation A offering. Please read the offering circular and related risks at invest.pacaso.com.-
The current trend is moderately bullish and BPMC is experiencing selling pressure, which indicates risk of future bearish movement.
Blueprint Medicines Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 99.24 | Sell |
| 20-day SMA: | 92.91 | Buy |
| 50-day SMA: | 89.55 | Buy |
| 200-day SMA: | 93.69 | Buy |
| 8-day EMA: | 98.08 | Sell |
| 20-day EMA: | 94.56 | Buy |
| 50-day EMA: | 92.36 | Buy |
| 200-day EMA: | 92.87 | Buy |
Blueprint Medicines Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 3.33 | Buy |
| Relative Strength Index (14 RSI): | 57.71 | Buy |
| Chaikin Money Flow: | -418427 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (82.69 - 98.55) | Buy |
| Bollinger Bands (100): | (84.92 - 103.92) | Buy |
Blueprint Medicines Technical Analysis
| May 1 | May 2 | May 5 | May 6 | May 7 | May 8 | May 9 | May 12 | May 13 | May 14 | |
|---|---|---|---|---|---|---|---|---|---|---|
| May | ||||||||||
| 01 | 02 | 05 | 06 | 07 | 08 | 09 | 12 | 13 | 14 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Blueprint Medicines Stock
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 97.51 while BPMC 8-day simple moving average is 99.24, which is a Sell signal.
-
The stock price of BPMC is 97.51 while Blueprint Medicines 20-day SMA is 92.91, which makes it a Buy.
-
Blueprint Medicines 50-day simple moving average is 89.55 while BPMC share price is 97.51, making it a Buy technically.
-
BPMC stock price is 97.51 and Blueprint Medicines 200-day simple moving average is 93.69, creating a Buy signal.
BPMC Technical Analysis vs Fundamental Analysis
Sell
49
Blueprint Medicines (BPMC)
is a Sell
Is Blueprint Medicines a Buy or a Sell?
-
Blueprint Medicines stock is rated a SellThe current Blueprint Medicines [BPMC] share price is $97.51. The Score for BPMC is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.
Blueprint Medicines Stock Info
Market Cap:
6.3B
Price in USD:
97.51
Share Volume:
424.3K
Blueprint Medicines 52-Week Range
52-Week High:
121.90
52-Week Low:
73.04
Sell
49
Blueprint Medicines (BPMC)
is a Sell
Blueprint Medicines Share Price Forecast
-
What is the Blueprint Medicines stock price today?The Blueprint Medicines stock price is 97.51 USD today.
-
Will BPMC stock go up or go down?Blueprint Medicines> share price is forecast to RISE/FALL based on technical indicators
-
Is Blueprint Medicines overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Blueprint Medicines is overvalued.
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 97.51 while BPMC 8-day exponential moving average is 98.08, which is a Sell signal.
-
The stock price of BPMC is 97.51 while Blueprint Medicines 20-day EMA is 94.56, which makes it a Buy.
-
Blueprint Medicines 50-day exponential moving average is 92.36 while BPMC share price is 97.51, making it a Buy technically.
-
BPMC stock price is 97.51 and Blueprint Medicines 200-day simple moving average is 92.87, creating a Buy signal.
Fundamental Analysis of Blueprint Medicines
Is Blueprint Medicines a good investment?
-
Analysts estimate an earnings increase this quarter of $0.67 per share, an increase next quarter of $0.33 per share, an increase this year of $0.60 per share, and an increase next year of $1.46 per share.
Technical Analysis of Blueprint Medicines
Should I short Blueprint Medicines stock?
-
BPMC Moving Average Covergence Divergence (MACD) indicator is 3.33, suggesting Blueprint Medicines is a Buy
-
Blueprint Medicines Relative Strength Index (RSI) is 57.71, which suggest Blueprint Medicines is overbought
-
The Bollinger Bands (25) for Blueprint Medicines is (82.69 - 98.55), which suggest Blueprint Medicines is a Buy
-
The Bollinger Bands (100) for Blueprint Medicines is (84.92 - 103.92), which suggest Blueprint Medicines is a Buy
* Blueprint Medicines stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.